The A-Z of Zika drug discovery

Autor(es):Mostrar menos -

Mottin, Melina ^[1] ; Borba, Joyce V. V. B. ^[1] ; Braga, Rodolpho C. ^[1] ; Torres, Pedro H. M. ^{[2, 3]} ; Martini, Matheus C. ^[4] ; Proenca-Modena, Jose Luiz ^[4] ; Judice, Carla C. ^[5] ; Costa, Fabio T. M. ^[5] ; Ekins, Sean ^[6] ; Perryman, Alexander L. ^[7] ; Andrade, Carolina Horta ^{[5, 1]}

Afiliação do(s) autor(es)

^[1] Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Drug Design, BR-74605170 Goiania, Go - Brazil

^[2] Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA - England

^[3] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, BR-21040900 Rio De Janeiro, RJ - Brazil

^[4] Univ Estadual Campinas, Lab Emerging Viruses LEVE, Dept Genet Evolut Microbiol & Immunol, Inst Biol, BR-13083864 Campinas, SP - Brazil

^[5] Univ Estadual Campinas, Lab Trop Dis Prof Dr Luiz Jacintho da Silva, Dept Genet Evolut Microbiol & Immunol, Inst Biol, BR-13083864 Campinas, SP - Brazil

^[6] Collaborat Pharmaceut Inc, 840 Main Campus Dr, Lab 3510, Raleigh, NC 27606 - USA

^[7] Rutgers State Univ, New Jersey Med Sch, Dept Pharmacol Physiol & Neurosci, Newark, NJ 07103 - USA

• Tipo de documento: Artigo de Revisão
• Fonte: DRUG DISCOVERY TODAY; v. 23, n. 11, p. 1833-1847, NOV 2018.
• Citações Web of Science: 10

Resumo

Despite the recent outbreak of Zika virus (ZIKV), there are still no approved treatments, and early-stage compounds are probably many years away from approval. A comprehensive A-Z review of the recent advances in ZIKV drug discovery efforts is presented, highlighting drug repositioning and computationally guided compounds, including discovered viral and host cell inhibitors. Promising ZIKV molecular targets are also described and discussed, as well as targets belonging to the host cell, as new opportunities for ZIKV drug discovery. All this knowledge is not only crucial to advancing the fight against the Zika virus and other flaviviruses but also helps us prepare for the next emerging virus outbreak to which we will have to respond. (AU)

• Processo FAPESP: 12/16525-2 - Plasmodium vivax: patogênese e infectividade
• Beneficiário: Fabio Trindade Maranhão Costa
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 16/00194-8 - Patogênese e neurovirulência de vírus emergentes no Brasil
• Beneficiário: José Luiz Proença Módena
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores
• Processo FAPESP: 17/02353-9 - Bioinformática, Quimiogenômica e Quimioinformática aplicados à Descoberta de Novos Fármacos e Produtos Biotecnológicos
• Beneficiário: Fabio Trindade Maranhão Costa
• Modalidade de apoio: Auxílio à Pesquisa - Pesquisador Visitante - Brasil
• Processo FAPESP: 16/13805-5 - Mecanismo de Ação da Lipoxina na Proteção do Desenvolvimento da Malária Cerebral Experimental
• Beneficiário: Fabio Trindade Maranhão Costa
• Modalidade de apoio: Auxílio à Pesquisa - Regular